Status:
UNKNOWN
Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Hyperglycemia
Hypotension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Glycemic imbalances are very common in shock patients admitted to intensive care units. A blood glucose control every 2 hours is routinely performed in patients requiring insulin therapy. In practice,...
Eligibility Criteria
Inclusion
- Patient in septic shock
- Arterial hypotension requiring noradrenaline
- Hyperglycaemia requiring insulin therapy
Exclusion
- Patients under guardianship, curatorship or deprived of liberty
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
September 11 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT04910841
Start Date
September 11 2023
End Date
June 1 2025
Last Update
October 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice
Nice, France